Advances in Computational Toxicology – Methodologies and Applications in Regulatory Science
This book provides a comprehensive review of both traditional and cutting-edge methodologies that are currently used in computational toxicology and specifically features its application in regulatory decision making. The authors from various government agencies such as FDA, NCATS and NIEHS industry, and academic institutes share their real-world experience and discuss most current practices in computational toxicology and potential applications in regulatory science. Among the topics covered are molecular modeling and molecular dynamics simulations, machine learning methods for toxicity analysis, network-based approaches for the assessment of drug toxicity and toxicogenomic analyses. Offering a valuable reference guide to computational toxicology and potential applications in regulatory science, this book will appeal to chemists, toxicologists, drug discovery and development researchers as well as to regulatory scientists, government reviewers and graduate students interested in this field.
Realizing the promise of computational prediction in toxicology applications
Journal Journal of Environmental Science and Health, Part C – March 19, 2019
Similarities and differences between variants called with human reference genome HG19 or HG38
BMC Bioinformatics – March 19, 2019
Computational prediction models for assessing endocrine disrupting potential of chemicals
Journal of Environmental Science and Health, Part C – January 11, 2019
Evotec and Immuneering to collaborate on artificial intelligence (“AI”) driven ligand identification for rare hereditary metabolic diseases
COMBINATION OF CUTTING-EDGE IPSC AND AI TECHNOLOGIES CREATES OPPORTUNITY TO DISCOVER NOVEL METABOLIC LIGANDS TO ACCELERATE DRUG DISCOVERY IN RARE METABOLIC DISEASES
Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a research collaboration with Immuneering Corporation (“Immuneering”), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases.
The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer’s disease
Cambridge, MA and London, 18 June 2018 – The Dementia Discovery Fund (“DDF”) and Immuneering Corporation (“Immuneering”) today announce they have entered into a joint research collaboration to identify novel drug targets and drug candidates for Alzheimer’s disease. As part of the collaboration, the DDF will invest $1.3 million for the use of Immuneering’s proprietary computational drug discovery platform to analyse publicly available data sets from Alzheimer’s disease patients. The goal of the collaboration is to identify clinically identifiable, mechanistically linked subpopulations within Alzheimer’s disease and generate new molecular entities (NMEs) that will ultimately lead to new medicines to treat Alzheimer’s disease.
Immuneering CEO Ben Zeskind to speak at 4th Cancer Cachexia Conference
June 11th, 2018 — Immuneering’s CEO (Ben Zeskind) is scheduled to present an invited talk entitled “Data-driven identification and optimization of new medicines for cancer cachexia” at the 4th Cancer Cachexia Conference on Sunday, September 16 2018 in Philadelphia, organized by the Cancer Cachexia Society. Immuneering is also proud to sponsor this important event, and to be a part of community of researchers working to develop effective treatments for this significant unmet need.
Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone
eNeurologicalSci – May 30, 2018
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Molecular Neurodegeneration – May 21, 2018
Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated through Molecular Dynamics Simulations
Frontiers in Pharmacology – May 15, 2018